Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era

Abstract Since 2004, multiple blockbuster drugs have been approved for men with metastatic prostate cancer. Nevertheless, it has been reported that no improvement in survival was observed between 2004 and 2009. Herein, we have analyzed the SEER database to assess the survival outcome of metastatic p...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Isaac E. Kim, Thomas L. Jang, Sinae Kim, David Y. Lee, Daniel D. Kim, Eric A. Singer, Saum Ghodoussipour, Mark N. Stein, Monish Aron, Marc A. Dall’Era, Isaac Yi Kim
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	metastatic prostate cancer M1 prostate cancer second‐line antiandrogens survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/f0308822a4d1411cbcaa1149414a27a7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f0308822a4d1411cbcaa1149414a27a7
record_format	dspace
spelling	oai:doaj.org-article:f0308822a4d1411cbcaa1149414a27a72021-11-22T09:08:47ZMarginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era2045-763410.1002/cam4.4074https://doaj.org/article/f0308822a4d1411cbcaa1149414a27a72021-11-01T00:00:00Zhttps://doi.org/10.1002/cam4.4074https://doaj.org/toc/2045-7634Abstract Since 2004, multiple blockbuster drugs have been approved for men with metastatic prostate cancer. Nevertheless, it has been reported that no improvement in survival was observed between 2004 and 2009. Herein, we have analyzed the SEER database to assess the survival outcome of metastatic prostate cancer patients since 2000. The results demonstrated that there was an improvement in both overall and prostate cancer‐specific survival for 4 months among men diagnosed with metastatic prostate cancer from 2010 to 2016 when compared to those in the pre‐2010 period. Interestingly, this survival benefit was limited to patients with bone and visceral metastasis (M1b and M1c stages). Collectively, our observation suggests that despite the new treatment agents such as second‐line antiandrogen therapies introduced in the modern era, the improvement in survival of metastatic prostate cancer patients has been surprisingly small.Isaac E. KimThomas L. JangSinae KimDavid Y. LeeDaniel D. KimEric A. SingerSaum GhodoussipourMark N. SteinMonish AronMarc A. Dall’EraIsaac Yi KimWileyarticlemetastatic prostate cancerM1 prostate cancersecond‐line antiandrogenssurvivalNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancer Medicine, Vol 10, Iss 22, Pp 7909-7920 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	metastatic prostate cancer M1 prostate cancer second‐line antiandrogens survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	metastatic prostate cancer M1 prostate cancer second‐line antiandrogens survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Isaac E. Kim Thomas L. Jang Sinae Kim David Y. Lee Daniel D. Kim Eric A. Singer Saum Ghodoussipour Mark N. Stein Monish Aron Marc A. Dall’Era Isaac Yi Kim Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era
description	Abstract Since 2004, multiple blockbuster drugs have been approved for men with metastatic prostate cancer. Nevertheless, it has been reported that no improvement in survival was observed between 2004 and 2009. Herein, we have analyzed the SEER database to assess the survival outcome of metastatic prostate cancer patients since 2000. The results demonstrated that there was an improvement in both overall and prostate cancer‐specific survival for 4 months among men diagnosed with metastatic prostate cancer from 2010 to 2016 when compared to those in the pre‐2010 period. Interestingly, this survival benefit was limited to patients with bone and visceral metastasis (M1b and M1c stages). Collectively, our observation suggests that despite the new treatment agents such as second‐line antiandrogen therapies introduced in the modern era, the improvement in survival of metastatic prostate cancer patients has been surprisingly small.
format	article
author	Isaac E. Kim Thomas L. Jang Sinae Kim David Y. Lee Daniel D. Kim Eric A. Singer Saum Ghodoussipour Mark N. Stein Monish Aron Marc A. Dall’Era Isaac Yi Kim
author_facet	Isaac E. Kim Thomas L. Jang Sinae Kim David Y. Lee Daniel D. Kim Eric A. Singer Saum Ghodoussipour Mark N. Stein Monish Aron Marc A. Dall’Era Isaac Yi Kim
author_sort	Isaac E. Kim
title	Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era
title_short	Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era
title_full	Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era
title_fullStr	Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era
title_full_unstemmed	Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era
title_sort	marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/f0308822a4d1411cbcaa1149414a27a7
work_keys_str_mv	AT isaacekim marginalimprovementinsurvivalamongpatientsdiagnosedwithmetastaticprostatecancerinthesecondlineantiandrogentherapyera AT thomasljang marginalimprovementinsurvivalamongpatientsdiagnosedwithmetastaticprostatecancerinthesecondlineantiandrogentherapyera AT sinaekim marginalimprovementinsurvivalamongpatientsdiagnosedwithmetastaticprostatecancerinthesecondlineantiandrogentherapyera AT davidylee marginalimprovementinsurvivalamongpatientsdiagnosedwithmetastaticprostatecancerinthesecondlineantiandrogentherapyera AT danieldkim marginalimprovementinsurvivalamongpatientsdiagnosedwithmetastaticprostatecancerinthesecondlineantiandrogentherapyera AT ericasinger marginalimprovementinsurvivalamongpatientsdiagnosedwithmetastaticprostatecancerinthesecondlineantiandrogentherapyera AT saumghodoussipour marginalimprovementinsurvivalamongpatientsdiagnosedwithmetastaticprostatecancerinthesecondlineantiandrogentherapyera AT marknstein marginalimprovementinsurvivalamongpatientsdiagnosedwithmetastaticprostatecancerinthesecondlineantiandrogentherapyera AT monisharon marginalimprovementinsurvivalamongpatientsdiagnosedwithmetastaticprostatecancerinthesecondlineantiandrogentherapyera AT marcadallera marginalimprovementinsurvivalamongpatientsdiagnosedwithmetastaticprostatecancerinthesecondlineantiandrogentherapyera AT isaacyikim marginalimprovementinsurvivalamongpatientsdiagnosedwithmetastaticprostatecancerinthesecondlineantiandrogentherapyera
_version_	1718417831271333888

Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era

Ejemplares similares